Company profile
Arrowhead Pharmaceuticals, Inc. Insider Trading
ARWREvery SEC Form 4 insider trading filing for Arrowhead Pharmaceuticals, Inc. (ARWR) since April 2023: open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC. Why 2023?
- Exchange
- Nasdaq
- Sector
- Pharmaceutical Preparations
- CIK
- 0000879407
- Filings
- 89
- Insiders
- 16
- Last filing
- 2026-08-18
Activity summary
No insider transactions in the last 30 days. The most recent was on August 18, 2026, when Michael S Perry sold 11,600 shares. 89 filings from 16 insiders are on record below.
Three year balance
Buy and sell value by quarter, Q4 23 to Q3 26. Arrowhead Pharmaceuticals, Inc. insiders are net sellers across the period shown.
Bars below the rule are sales, above are purchases. Largest quarter on the chart is $27.8M.
90 day insight
Over the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders sold $1.2M across 2 transactions with no open-market purchases.
- Most active insider: Michael S Perry with 1 transaction totaling $1.0M.
- Largest single sale: $1.0M by Michael S Perry on Aug 18, 2026.
Activity skews bearish: sales outpace buys.
Insider Transactions
Sourced from SEC EDGAR Form 4 filings. Updated hourly.
| Date | Insider | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Michael S Perry | ARWR | Sale | 11,600 | $87.30 | $1.01M |
| Aug 18, 2026 | Adeoye Y Olukotun | ARWR | Sale | 2,000 | $86.96 | $174K |
| Jun 15, 2026 | Matthew Gregory Cohen | ARWR | Award | 11,882 | — | — |
| May 12, 2026 | Hongbo Lu | ARWR | Sale10b5 | 2,970 | $76.88 | $228K |
| Apr 23, 2026 | James C Hamilton | ARWR | Sale10b5 | 10,000 | $75.00 | $750K |
45 more transactions hidden
Free account · No credit card required
Building something? Get API access →
Query this yourself
The same rows, over the API.
curl "https://api.form4api.com/v1/transactions?ticker=ARWR" \
-H "X-Api-Key: $KEY"Top insiders
By total value filed.
Institutional Ownership
Top 13F-HR holders of Arrowhead Pharmaceuticals, Inc. as of 2026-06-30
Data source: quarterly 13F-HR filings: institutional holders report positions within 45 days of quarter end. Joined with insider activity above: see who's loading up institutionally while insiders are trading. Full 13F-HR API →